Literature DB >> 10077438

Biodisposition characteristics of N-succinyl-chitosan and glycol-chitosan in normal and tumor-bearing mice.

K Kamiyama1, H Onishi, Y Machida.   

Abstract

Two water-soluble chitosan derivatives, N-succinyl-chitosan (Suc-chi; average MW 3x10(5)) and glycol-chitosan (Gly-chi; average MW 1.5x10(5)), were examined concerning their biodisposition characteristics in order to evaluate their possible use as water-soluble drug carriers. Their body distribution and urinary excretion were investigated by i.v. administration of FITC-labeled Suc-chi (FTC-Suc-chi) and FITC-labeled Gly-chi (FTC-Gly-chi) to normal and Sarcoma 180 solid tumor-bearing mice. In normal mice, both polymers showed good retention in blood circulation; especially, FTC-Suc-chi exhibited a long half-life of 51 h, and its distribution to other tissues was very small. FTC-Gly-chi was distributed into the kidney to a relatively high extent. In tumor-bearing mice, FTC-Suc-chi and FTC-Gly-chi were eliminated faster from the blood circulation than in normal mice, that is, with half-lives of 11 and 7 h, respectively. FTC-Suc-chi was less partitioned to the tumor tissue but accumulated more easily into it compared with FTC-Gly-chi. This suggested the enhanced permeability and retention (EPR) effect of Suc-chi and explained the previous result that a water-soluble Suc-chi-mitomycin C conjugate injected intravenously exhibited a good effect against Sarcoma 180 solid tumor. FTC-Gly-chi showed greater distribution to the kidney than in normal mice. Urinary excretion studies indicated the faster excretion of both polymers in tumor-bearing mice. The molecular weight of the products excreted into urine indicated that both polymers should be pretty resistant to the hydrolytic enzyme, lysozyme. Taking toxicities into account, Suc-chi is considered to be available as a drug carrier showing long systemic retention and tumor accumulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077438     DOI: 10.1248/bpb.22.179

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Zwitterionic chitosan derivatives for pH-sensitive stealth coating.

Authors:  Peisheng Xu; Gaurav Bajaj; Tyler Shugg; William G Van Alstine; Yoon Yeo
Journal:  Biomacromolecules       Date:  2010-09-13       Impact factor: 6.988

Review 2.  Chitin research revisited.

Authors:  Feisal Khoushab; Montarop Yamabhai
Journal:  Mar Drugs       Date:  2010-06-28       Impact factor: 5.118

Review 3.  Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action.

Authors:  Hari Sharan Adhikari; Paras Nath Yadav
Journal:  Int J Biomater       Date:  2018-12-30

4.  Low molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: synthesis, characterization and in vivo studies.

Authors:  Xia-kai He; Zhi-xiang Yuan; Xiao-juan Wu; Chao-qun Xu; Wan-yu Li
Journal:  Theranostics       Date:  2012-11-06       Impact factor: 11.556

5.  Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment.

Authors:  Nima Sepehri; Hasti Rouhani; Ahmad Reza Ghanbarpour; Mehdi Gharghabi; Faranak Tavassolian; Mohsen Amini; Seyed Nasser Ostad; Mohammad Hossein Ghahremani; Rassoul Dinarvand
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

Review 6.  Chitosan for gene delivery and orthopedic tissue engineering applications.

Authors:  Rosanne Raftery; Fergal J O'Brien; Sally-Ann Cryan
Journal:  Molecules       Date:  2013-05-15       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.